Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 9/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | QDPR | P09417 | 1/20 | 0.45 |
| ▸ | KIF11 | P52732 | 2/20 | 0.45 |
| ▸ | CYP21A2 | P08686 | 3/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2299673 | 0.84 | KIF11 (0.55) | CYP11B1CYP11B2LMNAKIF11IDO1 | |
| SCHEMBL257619 | 0.80 | KIF11 (0.49) | CYP11B1CYP11B2KIF11IDO1 | |
| SCHEMBL30285974 | 0.78 | ALDH1A1 (0.54) | CYP11B1CYP11B2LMNAMAPTKIF11 | |
| SCHEMBL1042606 | 0.78 | ALDH1A1 (0.54) | CYP11B1CYP11B2LMNAMAPTKIF11 | |
| SCHEMBL999759 | 0.78 | CYP11B1 (0.44) | CYP11B1CYP11B2KIF11IDO1 | |
| SCHEMBL28757717 | 0.77 | RAB9A (0.44) | CYP3A4MAPT | |
| SCHEMBL2852129 | 0.77 | KIF11 (0.55) | KIF11 | |
| SCHEMBL2741575 | 0.77 | KIF11 (0.46) | CYP11B1CYP11B2MAPTKIF11IDO1 | |
| SCHEMBL13036104 | 0.75 | CYP17A1 (0.50) | CYP17A1CYP11B1CYP11B2CYP3A4CYP19A1 | |
| SCHEMBL29180048 | 0.75 | MAPT (0.46) | CYP3A4LMNAMAPTQDPRKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575150-B2 | Triazole derivatives for treatment of Alzheimer's disease | MERCK SHARP & DOHME CORP. (US) | 2013-11-05 | — | — | US | disclosed |
| US-8288417-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2012-10-16 | — | — | US | disclosed |
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| US-8071624-B2 | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2378879-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010071741-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-06-24 | — | — | WO | disclosed |
| EP-1758580-A4 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| CN-1993128-A | N-substituted piperidines and their use as pharmaceuticals | INCYTE CORP (US) | 2007-07-04 | — | — | CN | disclosed |
| EP-1758580-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | Incyte Corporation (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006012226-A2 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | INCYTE CORPORATION (US) | 2006-02-02 | — | — | WO | disclosed |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | INCYTE CORPORATION | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040964-A1 | N-SUBSTITUTED PIPERIDINES AND THEIR USE AS PHARMACEUTICALS | HSD11B1, CYP11B1, HSD3B1 | CYP17A1 15/4885CYP11B1 2/4885CYP11B2 7/4885 |
| US-20060004049-A1 | N-substituted piperidines and their use as pharrmaceuticals | HSD11B1, HSD3B1, HSD11B2 | CYP17A1 8/4885CYP11B1 4/4885CYP11B2 11/4885 |
| US-20120022044-A1 | TRIAZOLE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MAPT, BACE1, APP | CYP17A1 286/4885CYP11B1 39/4885CYP11B2 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.